abstract |
Novel sulfoximine and sulfodiimine matrix metalloproteinase inhibitors of formula (I), wherein: R1 is selected from the group consisting of lower-alkyl, hydroxy lower-alkyl, amino lower-alkyl, carbamoyl lower-alkyl, lower-alkyl carbonyl, lower-alkyoxyalkyl, aralkyl and heteroaralkyl; X is NH or O; R2 is selected from the group consisting of hydrogen, lower-alkyl and aralkyl; R3 is selected from the group consisting of hydrogen, lower-alkyl, amino lower-alkyl, guanyl lower-alkyl, aralkyl and heteroaralkyl; and R4 is selected from the group consisting of lower alkyl, aralkyl and -CH(R5)-C(O)NH¿2?, wherein R?5¿ is selected from the group consisting of hydrogen, lower-alkyl, amino lower-alkyl, guanyl lower-alkyl, imidazoylalkyl, hydroxymethyl, 1-hydroxyethyl, mercapto lower-alkyl and methylthio lower-alkyl; useful for modulating physiological functions or treating diseases and disease conditions associated with matrix metalloproteinase modulation. |